"These studies remind us that most new #cancer drugs are of marginal benefit at best, despite their immense cost"—@RichardLehman1 @JAMAInternalMed https://t.co/WschOhcRt0 spot on re:
Accelerated approval @bishalgyawali @akesselheim
Surrogate endpoints @IamEmchee @VPrasadMDMPH pic.twitter.com/DMrThdLGum— Eric Topol (@EricTopol) May 28, 2019
Share this:
- Click to email a link to a friend (Opens in new window)
- Click to share on Twitter (Opens in new window)
- Click to share on Facebook (Opens in new window)
- Click to share on LinkedIn (Opens in new window)
- Click to print (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Skype (Opens in new window)